Meeting Banner
Abstract #4181

Myoinositol as a predictive baseline biomarker for overall survival of patients with recurrent glioblastoma treated with Bevacizumab: A 1H-magnetic resonance spectroscopy study.

Eike Steidl1,2,3, Oliver Baehr2,3, Joachim P. Steinbach2,3, Michael W. Ronellenfitsch2,3, Friedhelm Zanella1, Elke Hattingen1, and Ulrich Pilatus1

1Institute of Neuroradiology, Frankfurt am Main, Germany, 2Dr. Senckenberg Institute of Neurooncology, Frankfurt am Main, Germany, 3German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany

Myoinositol is an organic osmolyte, with intracellular concentration changes depending on the extracellular osmolality. Since Bevacizumab reduces tumor edema, we asked whether the Myoinositol concentration changes during therapy.

We used 1H-MRS to measure the Myoinositol concentrations in the tumor and contralateral control of patients with recurrent glioblastomas treated with Bevacizumab (n=30) and CCNU/VM26 (n=9).

Pre-therapeutic Myoinositol concentrations in the contralateral control were predictive of overall survival in patients treated with Bevacizumab. Furthermore our data confirm that recurrent glioblastoma show a strong metabolic reaction to Bevacizumab and support the hypothesis that Myoinositol might be a marker for early tumor cell invasion.

This abstract and the presentation materials are available to members only; a login is required.

Join Here